1. Home
  2. BATRK vs NUVB Comparison

BATRK vs NUVB Comparison

Compare BATRK & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlanta Braves Holdings Inc. Series C

BATRK

Atlanta Braves Holdings Inc. Series C

HOLD

Current Price

$38.65

Market Cap

2.5B

Sector

Industrials

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$8.55

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BATRK
NUVB
Founded
1991
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BATRK
NUVB
Price
$38.65
$8.55
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$58.00
$9.63
AVG Volume (30 Days)
313.9K
10.2M
Earning Date
11-05-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$723,307,000.00
$26,748,000.00
Revenue This Year
$12.40
$283.17
Revenue Next Year
$6.78
$340.98
P/E Ratio
N/A
N/A
Revenue Growth
6.62
1137.19
52 Week Low
$35.46
$1.54
52 Week High
$47.18
$8.70

Technical Indicators

Market Signals
Indicator
BATRK
NUVB
Relative Strength Index (RSI) 44.72 76.08
Support Level $38.00 $7.46
Resistance Level $39.98 $8.24
Average True Range (ATR) 0.74 0.62
MACD 0.06 0.13
Stochastic Oscillator 39.41 97.20

Price Performance

Historical Comparison
BATRK
NUVB

About BATRK Atlanta Braves Holdings Inc. Series C

Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: